歐比特(300053.SZ):04組衞星的發射時間需兼顧衞星調試、驗收、主管單位發射任務排期等多方面因素綜合確定,一直在積極推動及協調
格隆匯5月24日丨歐比特(300053.SZ)於2023年5月23日下午15:30-17:30接受機構調研,溝通交流中,就“珠海一號04組衞星目前是什麼進展?”,公司回覆稱,去年公司已完成了04組衞星構型和方案的基本設計,開展了1顆SAR衞星和3顆高光譜衞星的總體設計及各單機的詳細設計和研製,包括主要總體結構、佈局、指標、性能等,為了適配有關單位任務需求,對總體、關鍵載荷研製方案和發射進行了多次修改和調整。公司04組衞星的發射時間需兼顧衞星調試、驗收、主管單位發射任務排期等多方面因素綜合確定,公司一直在積極推動及協調有關事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.